Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 2018 September;60(3) > Panminerva Medica 2018 September;60(3):109-16



Opzioni di pubblicazione
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo



Panminerva Medica 2018 September;60(3):109-16

DOI: 10.23736/S0031-0808.18.03462-6


lingua: Inglese

Peroxisome proliferator-activated receptor gamma: promising target in glioblastoma

Gaurav GUPTA 1 , Gautam SINGHVI 2, Dinesh K. CHELLAPPAN 3, Sanjay SHARMA 4, Anurag MISHRA 5, Rajiv DAHIYA 6, Terezinha de JESUS ANDREOLI PINTO 7, Kamal DUA 8

1 School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, India; 2 Department of Pharmacy, Birla Institute of Technology and Science, Pilani, India; 3 Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia; 4 NMIMS, School of Pharmacy & Technology Management, Shirpur, India; 5 School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Jaipur, India; 6 Laboratory of Peptide Research and Development, School of Pharmacy, Faculty of Medical Sciences, The University of the West Indies, St. Augustine, Trinidad and Tobago; 7 Department of Pharmacy, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil; 8 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, Australia


Glioblastoma, also known as glioblastoma multiforme, is the most common and worldwide-spread cancer that begins within the brain. Glioblastomas represent 15% of brain tumors. The most common length of survival following diagnosis is 12 to 14 months with less than 3% to 5% of people surviving longer than five years. Without treatment, survival is typically 3 months. Among all receptors, special attention has been focused on the role of peroxisome proliferator-activated receptors (PPARs) in glioblastoma. PPARs are ligand-activated intracellular transcription factors. The PPAR subfamily consists of three subtypes encoded by distinct genes named PPARα, PPARβ/δ, and PPARγ. PPARγ is the most extensively studied subtype of PPAR. There has been interesting preliminary evidence suggesting that diabetic patients receiving PPARγ agonists, a group of anti-diabetics, thiazolidinedione drugs, have an increased median survival for glioblastoma. In this paper, the recent progresses in understanding the potential mechanism of PPARγ in glioblastoma are summarized.

KEY WORDS: PPAR gamma - Glioblastoma - Neoplasms - STAT3 transcription factor - Receptors, Wnt - Transforming growth factor beta

inizio pagina